Opinion|Videos|November 26, 2025
Role of Mechanisms of Action in Treatment Decisions and Personalized Care in Psorias
Explore the complexities of psoriasis treatment, including advanced therapies, mechanisms of action, and the potential of molecular testing for personalized care.
Advertisement
Episodes in this series
Panelists discuss the questions below in this video.
As treatment classes have expanded to target distinct immunologic pathways, how do differences in mechanism of action influence your sequencing and personalized treatment decisions?
Advertisement
Related to this article
A roundup of highlights from EADV Congress 2026 in Vienna, spanning dupilumab real-world data, pipeline biologics, and a first-in-class oral agent.
Among 155 patients aged 0 to 24 months, 96.1% of episodes were food-triggered and 90.4% of epinephrine recipients received only 1 dose.
In a LIBERTY post hoc analysis, most patients restarting infliximab as SC 240 mg after a drug holiday had prior ADAs, yet outcomes were similar.
US claims data from Fall Clinical 2026 suggest hidradenitis suppurativa symptoms occur at similar rates in both sexes, hinting at underdiagnosis in males.
At the standard 100 ng/mL threshold, FIT detected 62.0% of colorectal cancers in women vs 77.4% in men, with proximal tumors driving much of the gap.
Clinicians at CHEST 2026 will see late-breaking COPD, asthma, pulmonary hypertension, and bronchoscopy data, plus exclusive expert interviews.
A Cell Reports mouse study found hepatic steatosis fell without weight loss through separate iNKT cell and GLP-1 pathways.
Catch up on HCPLive’s top EADV 2026 psoriasis coverage, from head-to-head TYK2 inhibitor data to 2-year oral IL-23 results in high-impact disease sites.
Advertisement
Advertisement
Trending on HCPLive
1
Efruxifermin Shows Durable Antifibrotic Response in MASH Through 96 Weeks
2
Oral Icotrokinra Sustains UC Response Through 76 Weeks in ANTHEM-UC LTE
3
Eplontersen Fails to Achieve Primary Endpoint, Improves KCCQ and 6MWT in ATTR-CM
4
Tovinontrine 50 mg Improves cGMP With Minimal Effect on NT-proBNP in HFpEF
5